Crossmark

Meloxicam with Filgrastim may Reduce Oxidative Stress in Hematopoietic Progenitor Cells during Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma

Crossref DOI link: https://doi.org/10.1007/s12015-021-10259-y

Published Online: 2021-09-12

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Patterson, Andrea M.

Zhang, Shuhong

Liu, Liqiong

Li, Hongge

Singh, Pratibha

Liu, Yunlong

Farag, Sherif S.

Pelus, Louis M. https://orcid.org/0000-0001-8376-4425
Funding

Funding for this research was provided by:

National Cancer Institute (CA182947)
License Information

Text and Data Mining valid from 2021-09-12

Version of Record valid from 2021-09-12
More Information

Article History

Accepted: 2 September 2021

First Online: 12 September 2021

Declarations

:

: The authors have no conflicts of interest to declare that are relevant to the content of this article.

: The clinical trial was approved by the Institutional Review Board of Indiana University. Investigative use of patient samples was approved by the IUPUI/Clarian Institutional Review Board and the Indiana University Institutional Biosafety Committee.

: IRB approved; all patients gave written informed consent.

: All patients gave written informed consent.

Document is current

Any future updates will be listed below